Sanofi India MD Rodolfo Hrosz to Step Down on April 30, 2025

Sanofi India has announced a major leadership change, with Managing Director Rodolfo Hrosz set to step down at the end of April 2025. The move is part of an internal transition within the Sanofi group.

Leadership Transition Announced

Sanofi India Limited announced on April 9, 2025, that Managing Director Rodolfo Hrosz will step down from his position effective April 30, 2025. The company confirmed this change in a regulatory filing, stating that Hrosz is taking up a new assignment within the Sanofi group.

The board of directors accepted his resignation during a meeting held on April 9, and expressed appreciation for his contributions. Hrosz will also cease to be a key managerial personnel, senior management personnel, and a member of the board committees from the close of business on April 30.

Appointment as Non-Executive Director

Following his resignation as Managing Director, the board has approved Hrosz’s appointment as an additional non-executive director with effect from May 1, 2025, subject to shareholder approval. This move was made based on the recommendation of the Nomination and Remuneration Committee.

Sanofi India said the process to appoint a successor to the role of managing director will be initiated in due course. Details of Hrosz’s new responsibilities within the group were not disclosed.

Sanofi India Share Price Performance

As of the end of trading on April 9, 2025, Sanofi India’s shares closed at ₹6,080.10 on the NSE, reflecting a 1.66% loss. The Deliverable/Traded Quantity stood at 37.76%, and the company’s market capitalisation is ₹14,002.85 crore.

Conclusion

The departure of Rodolfo Hrosz marks a significant change in leadership at Sanofi India. While the company has not yet named a successor, the board’s decision to retain Hrosz as a non-executive director suggests continuity in strategic direction during the transition.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.